Cancer cell study breakthroughTanya Thompson
Cancer - Diagnosis, Treatment, Prevention: Greater insight into the causes and mechanisms of cancer has led to better ways to diagnose and treat the many forms of this disease. First of all, advances in detection have improved the ability to discover can
HANSIZHUANG (serplulimab) is the first innovative mAb developed by Henlius. Since launched in March 2022, HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumours, sqNSCLC, extensive-stage s...
HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumours, sqNSCLC, extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), benefiting more than 51,000 patients. In December 2023, HANSIZHUANG was approved ...
CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups. Ulrich Blache ...
Cancer immune-cell therapies are increasing in prominence as breakthrough treatments. Since 2017, several chimeric antigen receptor (CAR) T-cell therapies have been approved and have demonstrated excellent therapeutic efficacy in haematologic malignancies. All of the currently approved CAR T-cell therapies...
When a cancer cell doesn't respond to traditional therapies, doctors may turn to a sort of viral biological warfare, by deploying 'troops' in the form of viral agents that are specifically engineered to target and eliminate cancer cells. The mode of attack is to transform the tumor...
Throughout August, the FDA approved drugs for the treatment of diseases including non-small cell lung cancer, cutaneous T-cell lymphoma, astrocytoma/oligodendroglioma, and endometrial cancer. GSK5764227 Receives Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer Kristi Rosa Septemb...
CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups. ...
(and subsequently for all NSCLC histological types) after the first-line treatment with platinum doublet chemotherapy had failed. Under normal conditions, the immune checkpoint receptor programmed cell death-1 (PD-1) is expressed on activated T cells. PD-1 inhibits immunological responses from being...